Bruker (BRKR) vs Pacific Biosciences of California (PACB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pacific Biosciences of California (PACB) has outperformed Bruker (BRKR) over the past year, gaining 94.3% versus a gain of 72.8%. Over five years, BRKR leads with a -22.7% price change compared with -88.8% for PACB. Bruker is the larger company by market cap ($9.10 billion vs $845.5 million), about 10.8 times the size.
Bruker pays a dividend yielding 0.33%, while Pacific Biosciences of California does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BRKR | PACB |
|---|---|---|
| Share price | $59.72 | $2.72 |
| Market cap | $9.10B | $845.46M |
| 1-day change | -1.29% | +0.74% |
| YTD return | +26.77% | +45.45% |
| 1-year return | +72.80% | +94.29% |
| 5-year return | -22.67% | -88.85% |
| Forward P/E | 24.76 | — |
| EPS (TTM) | $-0.70 | $-0.43 |
| Dividend yield | 0.33% | 0.00% |
| Annual dividend | $0.20 | $0.00 |
| Revenue (latest FY) | $3.44B | — |
| Revenue growth (YoY) | +2.08% | — |
| Net income (latest FY) | $-8.60M | — |
| Gross margin | 45.91% | — |
| Operating margin | 1.98% | — |
| Net margin | -0.25% | — |
| 52-week high | $66.98 | $3.44 |
| 52-week low | $32.37 | $1.07 |
| Distance from 52-week high | -10.84% | -20.93% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +5.91% | -20.59% |
| Average volume | 2.23M | 10.10M |
| Shares outstanding | 152.36M | 310.83M |
| Employees | 11,085 | 485 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Bruker is about 10.8 times larger than Pacific Biosciences of California by market value ($9.10B vs $845.46M).
- PACB has outperformed BRKR by 21.5 percentage points over the past year.
About Bruker
BRKR stock →Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Industrials · Biotechnology: Laboratory Analytical Instruments · 11,085 employees
About Pacific Biosciences of California
PACB stock →Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems.
Industrials · Biotechnology: Laboratory Analytical Instruments · 485 employees
BRKR vs PACB FAQ
Which is bigger, Bruker or Pacific Biosciences of California?
Bruker (BRKR) is larger, with a market capitalization of $9.10B compared with $845.46M for Pacific Biosciences of California (PACB).
Which stock has performed better over the past year, BRKR or PACB?
PACB returned +94.29% over the past 12 months, compared with +72.80% for BRKR (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Bruker or Pacific Biosciences of California?
Bruker pays a dividend yielding 0.33%, while Pacific Biosciences of California does not currently pay a regular dividend.
Are Bruker and Pacific Biosciences of California in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.